

CURRICULUM VITAE

Henry Mark Kwong, Jr., M.D.

EDUCATION

Washington University in St. Louis	B.S in Chem Eng	8/93-5/97
Tulane University School of Medicine	M.D.	8/99-5/03
Tulane Department of Surgery	Internship	7/03-6/04
Tulane Department of Ophthalmology	Residency	7/04-6/07
Associated Retina Consultants, Ltd.	Retina Fellow	7/07-6/09

(Certified through Association of University Professors of Ophthalmology)

WORK EXPERIENCE

Associated Retina Consultants, Ltd.

Private Practice Physician

1750 E Glendale Ave

Phoenix, Arizona 85020

Dates 7/1/2009 – Present

Clinical Assistant Professor in the Department of Ophthalmology | University of Arizona,
Phoenix, Arizona

Assistant Director of Fellowship Program | Associated Retina Consultants, Ltd., Phoenix Arizona
Section Chief | Banner Good Samaritan Medical Center, Phoenix, Arizona

PREVIOUS WORK EXPERIENCE

Fellowship 2007-2009 Associated Retina Consultants
1750 E Glendale Ave
Phoenix, AZ 85020

ORGANIZATIONS AND SOCIETIES

- American Academy of Ophthalmology
- American Board of Ophthalmology
- American Society of Retina Specialists
- Arizona Ophthalmological Society
- Phoenix Ophthalmological Society
- Omega Chi Epsilon – Chemical Engineering Honorary Society

AWARDS

2007 Tulane Dept. Of Ophthalmology C.S. O'Brien Resident Research Award

RESEARCH EXPERIENCE

Alcon Research, Ltd., Protocol C-02-60: An Evaluation of the Efficacy and Safety of Posterior Juxtapalpebral Administrations of Anecortave Acetate for Depot Suspension (15mg or 30 mg) versus Sham Administration in Patients (Enrolled in Study "A" or Study "B") at Risk for Developing Sight-Threatening Choroidal Neovascularization (CNV) Due to Exudative Age-Related Macular Degeneration. Sub-Investigator, Phoenix, AZ. 2007

Alcon Research, Ltd., Protocol C-10-083: Safety and Efficacy of ESBA1008 versus Lucentis® for the Treatment of Exudative Age-Related Macular Degeneration. Sub-Investigator, Phoenix, AZ. 2011

Allergan, Inc. GMA-OZU-09-011: A Retrospective Data Collection Study in Patients Receiving Two or More Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Retinal Vein Occlusion. Phoenix, AZ. 2011

Eli Lilly and Company, Protocol B7A-MC-MBCU: The Effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography. Sub-Investigator, Phoenix AZ. 2009

Genentech, Inc., Protocol FVF3426g (HORIZON): An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed the Treatment Phase of A Genentech-Sponsored Ranibizumab Study. Sub-Investigator, Phoenix, AZ. 2007

Genentech, Inc., Protocol FVF4168g (RIDE): A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus. Sub-Investigator, Phoenix, AZ. 2009

Genentech, Inc., Protocol FVF4579g (HARBOR): A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Sub-Investigator, Phoenix, AZ. 2009

Genentech, Inc., Protocol FVF4967g (SHORE): A multicenter randomized study evaluating dosing regimens for treatment with intravitreal ranibizumab injections in subjects with macular edema following retinal vein occlusion. Sub-Investigator, Phoenix, AZ. 2011

GlaxoSmithKline, Protocol BAM114341: A phase 2, multi-centre, randomized, double-masked, placebocontrolled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMS). Sub-Investigator, Phoenix, AZ. 2011

GlaxoSmithKline, Protocol MD7110852: A Phase 2b Dose-Evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration. Sub-Investigator, Phoenix, AZ. 2009

LPATH LT1009-Oph-003 (Nexus): A Phase 2A, Multi-Center, Masked, Randomized, Comparator-Controlled Study Evaluating iSONEP™ (Sonepcizumab [LT1009]) as Either Monotherapy or Adjunctive Therapy to Lucentis® or Avastin® Versus Lucentis® or Avastin® Alone in the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Phoenix, AZ. 2011

Opko Health, Inc.: A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Monotherapy Every 4 Weeks in Patients with Exudative Age-related Macular Degeneration (AMD). Sub-Investigator, Phoenix, AZ. 2008

Regeneron Pharmaceuticals, Inc., Protocol VGFT-OD-0605: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration. Sub-Investigator, Phoenix, AZ. 2008

Regeneron Pharmaceuticals, Inc., Protocol VGFT-OD-0702: An Open-Label, Long-Term, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration. Sub-Investigator, Phoenix, AZ. 2009

Regeneron Pharmaceuticals, Inc., Protocol VGFT-OD-0819: A Randomized, Double-Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administrations of VEGF TrapEye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). Sub-Investigator, Phoenix, AZ. 2009

Regeneron Pharmaceuticals, Inc., Protocol VGFT-OD-0910: An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration. Sub-Investigator, Phoenix, AZ. 2010

Regeneron Pharmaceuticals, Inc., Protocol VGFT-OD-1009: A Double-Masked, Randomized, ActiveControlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema. Principal Investigator, Phoenix, AZ 2011

Thrombogenics, Inc., Protocol TG-MV-006: A Randomized, Placebo Controlled, Double-Masked, Multicenter Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. SubInvestigator, Phoenix, AZ. 2009

PRESENTATIONS/PUBLICATIONS

Kwong HM, Ayyala RS, Efficacy of Selective Laser Trabeculoplasty in a Heterogeneous Population – 1 year results. *40th Annual O'Brien Presentation Research Day*, Tulane University, New Orleans, LA, June 2005

Kwong HM, Surgical Techniques – Lecture and Wet lab. Basic Sciences Course, Tulane Department of Ophthalmology, New Orleans LA, July 2005

Kwong HM, Karcioğlu ZA, Uveal Melanoma in Women with Breast Carcinoma. Presented at the *American Academy of Ophthalmology Annual Meeting*, Chicago, IL, October 2005

Chilakapati M, Kwong HM, Chevez-Barrios P, Coats DK, Recurrent Orbital “Cellulitis” Interactive Case Series. *Medscape Ophthalmology*, March 2006

Kwong HM, Coats DK, Effect of Surgical Approach on Post-Operative Pain in Strabismus Patients. *43th Annual Cullen Eye Institute/ Baylor Ophthalmology Research Day*, Baylor College of Medicine, Houston TX, June 2006

Kwong HM, Manzano R, Peyman GA, et al., Ocular Toxicity of Intravitreal Adalimumab (Humira) in the Rabbit Presented at the *Association for Research in Vision and Ophthalmology Annual Meeting*, Fort Lauderdale, FL, May 2007

H.M. Kwong, N. Herbots, R.J. Culbertson, D.A. Sell, A.M. Murphy, R.B. Bennett-Kennett, S.D. Whaley, C.H. Sell, MD & T. Kutz, A.S. Benitez, M.A. Hart, B.J. Wilkens. Oral presentation at the 58th International American Vacuum Society Symposium Bio-materials Interfaces Division, *Controlling the Hydroaffinity of Silicone/Hydrophobic Acrylic Surfaces of Intra-ocular Lenses using Visco-Elastic Colloids and Blood Proteins*, Nashville, TN, October 31-November 4th, 2011

H.M. Kwong, Jr., MD, M.A. Hart, D. A. Sell, J. D. Bradley, N. Herbots, R. J. Culbertson, C. H. Sell, MD, Mechanism Of Condensation And Hydroaffinity In Si-Based Surfaces For Medical Implants Via Surface Energy Modification During IBA Of Si, Si Oxides, & Silicone, Contact Angle Analysis And Hydrated Polymer Adsorption. *Q.X. Bradley*, IBMM 2010, Montreal August 22-25, 2010.

H.M. Kwong, N. Herbots, M.A. Hart, D.A. Sell, J.D. Bradley, B.J. Wilkens, C.H. Sell, R.J. Culbertson, and S.D. Whaley, “Ion Beam Analysis of Silicon-Based Surfaces and Correlation with Surface Energy Measurements,” *Q. Xing*, 21st International Conference on the Application to Accelerators in Research and Industry (CAARI), Dallas/Fort Worth, TX, August 8-13, 2010.

H.M. Kwong, MD, T. T. Kutz, A. Murphy, A.S. Benitez, D.A. Sell, R.J. Culbertson, N. Herbots, C.H. Sell, MD, Ion Beam Analysis of Silicon-Based Materials and Correlation to the Role of Blood Protein Contamination
Updated 8/20/2018

on Hydrophilic Properties *R. B. Bennett-Kennett*, ASU 7th Annual Physics Undergraduate Research Symp. (April 29, 2011)

H.M. Kwong, MD, D.A. Sell, T. T. Kutz, A.S. Benitez, , R. B. Bennett-Kennett, R.J. Culbertson, N. Herbots, C.H. Sell, MD, Controlling The Hydroaffinity Of Silicone/Hydrophobic Acrylic Surfaces Of Intraocular Lenses Using Visco-Elastic Colloids And Blood Proteins *A.M. Murphy*,. ASU 7th Ann. Physics Undergrad. Res. Symp. (April 29, 2011)

K. Turaka, J. S. Bryan, H. M. Kwong Jr., S. De Souza, A. J. Gordon, R. Reddy, M. C. Ziemianski, C. H. Sell. Vitreoretinal Lymphoma: Changing Trends in Diagnosis and Local Treatment Modalities. Poster presentation (#3074) at 54th American Society for Therapeutic Radiation Oncology (ASTRO) 2012 Annual Meeting, Boston, MA October 28-31, 2012.

Kiran Turaka, Alan J. Gordon, J. Shepard Bryan, Henry M. Kwong Jr., Stephen De Souza, Rahul Reddy, Matthew C. Ziemianski, Clive H. Sell. Vitreoretinal Lymphoma and Intravitreal Chemotherapy: Ocular and Systemic Outcomes. Poster presentation at the Pan Pacific Lymphoma Conference (PPLC), July 17-20, 2012, Island of Maui, Hawaii. Received the Travel grant award for the poster presentation.

Turaka K, Bryan JS, Kwong HM Jr, Ziemianski MC. Bilateral occlusive retinal vasculitis in a patient with primary antiphospholipid antibody syndrome. *Can J Ophthalmol*. 2012 Dec;47(6):e60-1.

Turaka K, Bryan JS, De Souza S, Gordon AJ, Kwong HM Jr, Ziemianski MC, Reddy R, Sell CH. Vitreoretinal Lymphoma: Changing Trends in Diagnosis and Local Treatment Modalities at a Single Institution. *Clin Lymphoma Myeloma Leuk*. 2012 Dec;12(6):412-7 [Epub 2012 Sep 18].

K. Turaka, J. S. Bryan, H. M. Kwong Jr., S. De Souza, A. J. Gordon, R. Reddy, M. C. Ziemianski, C. H. Sell. Vitreoretinal Lymphoma: Changing Trends in Diagnosis and Local Treatment Modalities. *Int J Rad Oncol Biol Phys* 2012; 1 Nov (35) 84:S621-22.

Turaka K, Bryan JS, Gordon AJ, Kwong HM Jr, Reddy R, Tsipursky M, Sell CH. Clinical and image-guided chorioretinal findings in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. *J Pediatr Endocrinol Metab* 2012; 25(5-6):565-7.

Turaka K, Bryan JS, Gordon AJ, Reddy R, Kwong HM Jr, Sell CH. Laser pointer induced macular damage: case report and mini review. *Int Ophthalmol* 2012 Jun; 32(3):293-7. Epub 2012 Apr 1.

Turaka K, Gordon AJ, Patel S, Bryan JS, Kwong HM Jr, Dugel PU, Arogyasami RM. Diagnostic and therapeutic challenges. *Retina*. 2013 Mar;33(3):661-5.

Turaka K, Kwong HM Jr, De Souza S. Intravitreal implant migration into anterior chamber in a postvitrectomy eye with central retinal vein occlusion and persistent macular edema. *Ophthalmic Surg Lasers Imaging Retina*. 2013 Mar-Apr; 44(2):196-7.